Swiss Auto Components Stock News

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...

Key Insights The projected fair value for Logitech International is CHF121 based on 2 Stage Free Cash Flow to Equity...

Key Insights Significant control over Sunrise Communications by individual investors implies that the general public...

As the pan-European STOXX Europe 600 Index edges closer to record highs amid optimism about future earnings and economic prospects, investors are keenly observing the high-growth tech sector, which remains a focal point of innovation and potential. In such an environment, identifying promising stocks often involves looking for companies with robust growth trajectories and adaptability to evolving technological trends, making them standouts in a dynamic market landscape.

As the pan-European STOXX Europe 600 Index edged slightly higher in a holiday-shortened week, optimism about future earnings and economic conditions has kept investor sentiment buoyant. In this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors looking to capitalize on market inefficiencies.

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Key Insights Institutions' substantial holdings in Galderma Group implies that they have significant influence over the...

Straumann Holding AG ( VTX:STMN ) received a lot of attention from a substantial price movement on the SWX over the...

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...

EMS-CHEMIE HOLDING AG's ( VTX:EMSN ) price-to-earnings (or "P/E") ratio of 27.6x might make it look like a sell right...

Earlier this month, Genentech, a member of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies, cutting administration time from hours to about one minute. This approval not only broadens Roche’s oncology offering but also highlights how treatment convenience and clinic efficiency are becoming core differentiators in cancer...

Alcon (SWX:ALC) has quietly outperformed the broader healthcare space over the past month, with shares climbing about 4% even as the stock remains down sharply year to date. See our latest analysis for Alcon. That recent 30 day share price return of 3.84% looks more like a stabilisation than a full reversal. The year to date share price is still down 16.42%, and the one year total shareholder return is negative but modestly positive over three years. If Alcon’s move has you reassessing the...

Lonza Group AG ( VTX:LONN ) saw significant share price movement during recent months on the SWX, rising to highs of...

Idorsia Ltd ( VTX:IDIA ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. The...

With its stock down 7.7% over the past month, it is easy to disregard Adecco Group (VTX:ADEN). Given that stock prices...

UBS Group AG recently outlined further Credit Suisse integration steps, including multi-wave job cuts through 2026 and leadership changes in operations and technology, with Group Technology set to report to incoming Group Chief Operating Officer Beatriz Martin from January 2026. By consolidating technology under the Group COO and emphasizing artificial intelligence and IT migration, UBS is signaling a push to streamline operations while completing the complex Credit Suisse integration. We’ll...

Key Insights The projected fair value for Amrize is CHF82.29 based on 2 Stage Free Cash Flow to Equity Current share...

If you are wondering whether Novartis is still attractively priced today, or if most of the upside has already gone to earlier investors, you are in the right place to unpack what the current market is really pricing in. Novartis has quietly been rewarding patient shareholders, with the stock up 1.7% over the last week, 5.6% over the past month, and 21.0% year to date, adding to a 28.2% gain over 1 year, 50.6% over 3 years, and 75.4% over 5 years. Those gains sit against a backdrop of...

If you are wondering whether UBS Group still looks attractive after its recent strong performance, or whether you may be arriving late to the party, this breakdown can help you consider whether the current share price aligns with the underlying value. The stock has climbed 8.3% over the last week, 16.0% over the past month, and is now sitting on a 32.9% gain over the last year, with a 125.6% return over 3 years and 227.0% over 5 years reshaping expectations around its long term potential and...

EPIC Suisse (SWX:EPIC) has just raised CHF 70 million through a follow on equity offering at CHF 80 per share, a move that directly affects both its growth options and shareholder dilution. See our latest analysis for EPIC Suisse. The fresh capital raise comes on the back of a steady share price return so far this year and a much stronger 1 year total shareholder return of 11.57 percent, suggesting confidence in EPIC Suisse’s long term real estate strategy. If this equity deal has you...

Holcim recently completed two acquisitions and agreed a third in demolition materials recycling across the UK, Germany and France, adding around 1.3 million tons of annual permitted processing capacity to accelerate its ECOCycle® circular construction platform in Europe. By linking these recycling businesses into its existing network, including prior UK and continental European deals, Holcim is deepening local access to circular construction services in major urban and infrastructure...

Wondering if Kuehne + Nagel International is quietly turning into a value opportunity, or if the recent interest is just noise? Let us unpack what the current share price is really telling you. After a rough stretch that still leaves the stock down 15.3% year to date and 10.5% over the last year, the shares have bounced with gains of 6.5% in the last week and 13.4% over the past month. Those moves come as investors refocus on global trade normalising, ongoing supply chain recalibration after...

Partners Group recently reported its Assets under Management as of 31 December 2025 and confirmed it will host a 2025 Business Update and 2026 Outlook presentation on 14 January 2026, offering fresh detail on its operations and plans. This combination of an AuM disclosure and upcoming outlook briefing gives investors a clearer window into how the firm is positioning its private-markets platform for the next phase of growth and product development. We’ll now explore how the latest AuM...

Today is shaping up negative for Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shareholders, with the analysts delivering...